A 56-Year-Old Female With Recurrent Ovarian Cancer

The completion of a new drug application for the combination of avutometinib and defactinib in KRAS-mutant ovarian cancer is expected to be finalized with the FDA by the end of the month.

In season 2, episode 6 of Targeted Talks, Alexander B. Olawaiye, MD leads a discussion with Haider S. Mahdi, MD, about the modern approaches to treating cervical and endometrial cancers.

While the phase 3 ENGOT-en11/GOG-3053/KEYNOTE-B21 trial missed its end point of disease-free survival, benefits were still observed in the dMMR subgroup.

Sarah M. Temkin, MD leads discussion with Daphne B. Stewart, MD, around targeted therapies in ovarian cancer, whether offered in the academic or community setting.

In FRα-positive, platinum-resistant ovarian cancer, mirvetuximab soravtansine showed improvements in progression-free survival, overall response rate, and overall survival.

Pembrolizumab plus concurrent chemoradiotherapy demonstrated a higher progression-free survival rate than placebo plus concurrent chemoradiotherapy for patients with high-risk, locally advanced cervical cancer in the East Asia subgroup of the phase 3 ENGOT-cx11/GOG-3047/KEYNOTE-A18 study.